November 18, 2026
Health news, explained with evidence
LIVE

Preclinical Study Identifies Potential Drug Combinations for Nontuberculous Mycobacterial Lung Disease

🔬 Research 2 min read 👁 3

Researchers at Colorado State University evaluated standard tuberculosis drugs using a tiered screening framework and identified bedaquiline-anchored regimens that show cross-species efficacy against nontuberculous mycobacterial pulmonary infections.

🔬Research

Key points

  • Evaluated 11 standard tuberculosis drugs against NTM species using a tiered preclinical screening framework.
  • Identified bedaquiline as a strong therapeutic anchor maintaining activity despite inducible macrolide resistance.
  • Found that optimized three-drug combinations of bedaquiline, azithromycin, and ofloxacin yielded significant bacterial clearance in animal models.

Investigators at Colorado State University have published a preclinical study identifying potential therapeutic regimens for nontuberculous mycobacterial (NTM) pulmonary disease, a chronic condition caused by pathogens such as Mycobacterium avium and Mycobacterium abscessus. Current treatments often involve prolonged courses, potential adverse effects, and suboptimal outcomes. To find more effective options, the research team systematically screened eleven standard tuberculosis drugs using minimum inhibitory concentration testing, intracellular macrophage infection assays, and species-matched murine lung infection models.

The evaluation highlighted significant variations in drug susceptibility between the slow- and rapidly growing NTM species. Among the compounds tested, the FDA-approved antimycobacterial drug bedaquiline (BDQ) exhibited the strongest and most consistent activity, serving as a reliable therapeutic anchor that maintained its efficacy despite inducible macrolide resistance in M. abscessus. Azithromycin (AZI), clarithromycin (CLA), and ofloxacin (OFL) also showed promise, though macrolides demonstrated increased minimum inhibitory concentrations upon extended incubation.

Subsequent combination and murine infection studies pointed to BDQ as the primary driver of antibacterial success. Two-drug combinations including BDQ plus AZI or OFL demonstrated activity across species-matched models, while an optimized three-drug regimen of BDQ, AZI, and OFL achieved the highest level of bacterial clearance in the M. abscessus model. These early-stage preclinical findings, supported by the National Institute of Allergy and Infectious Diseases, suggest a framework for developing modular therapeutic platforms, though further clinical evaluation is necessary to determine applicability in humans.

What to know: NTM pulmonary infections are difficult to treat with current therapies. This preclinical animal study suggests that bedaquiline-based drug combinations may improve bacterial clearance, but these early findings have not yet been tested in human clinical trials. Readers should consult a qualified healthcare provider for any personal medical decisions or treatment questions.

Source Nature Health Sciences — nature.com/articles/s41598-026-79568-x ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.